[1]
|
Hudson, J.I., Perahia, D.G., Gilaberte, I., Wang, F., Watkin, J.G. and Detke, M.J. (2007) Duloxetine in the treatment of major depressive disorder: An open-label study. BMC Psychiatry, 7(1), 43. http://www.biomedcentral.com
|
[2]
|
Williams, R.H.M. (2005) Duloxetine (Cymbalta): a new treatment option in depression. Prescriber, 16(12), 49-50.
http://www.escriber.com
|
[3]
|
McIntyre, R.S., Muller, A., Mancini, D.A. and Silver, E.S. (2003) What to do it an initial antidepressant fails. Canadian Family Physician, 49(4), 449-457.
|
[4]
|
Gartlehner, G., Hansen, R.A., Kahwati, L., et al. (2006) Drug class review on second generation antidepressants Final Report March. Oregan Evidance based Practice Centre, Oregan Health & Science University, Portland.
|
[5]
|
Detke, M.J., Lu, Y., Goldstein, D.J., Hayes, J.R. and Demitrack, M.A. (2002) Duloxetine, 60 mg once daily for major depressive disorder: a randomized double blind placebo controlled trial. Journal of Clinical Psychiatry, 63(4), 308-315.
|
[6]
|
Detke, M.J., Lu, Y., Goldstein, D.J., McNamara, R.K. and Demitrack, M.A. (2002) Duloxetine, 60 mg once daily dosing versus placebo in the acute treatment of major depression. Journal of Psychiatric Research, 36(6), 383-390.
|
[7]
|
Goldstein, D.J., Mallinckrodt, C., Lu, Y., Demitrack and M.A. (2002) Duloxetine in the treatment of major depressive disorder: A double blind clinical trial. Journal of Clinical Psychiatry, 63(3), 225-231.
|
[8]
|
Raskin, J., Goldstein, D.J., Mallinckrodt, C.H. and Ferguson, M.B. (2003) Duloxetine in the long term treatment of major depressive disorder. Journal of Clinical Psychiatry, 64(10), 1237-1244.
|
[9]
|
Kirwin, J.L. and Gören, J.L. (2005) Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder. Pharmacotherapy, 25(3), 396-410.
|
[10]
|
Depressive Episode F-32 (1992) The ICD-10 classification of mental and behavioural disorders, diagnostic criteria for research. World Health Organization, Geneva. 81-85.
|
[11]
|
Blacker, D. (2005) Psychiatric rating scales. In. Kaplan, H.I. and Sadock, B.J. Eds. Comprehensive textbook of Psychiatry, 8th Edition, Williams and Wilkins, Baltimore.
|
[12]
|
Segal, Z.V., Pearson, J.L. and Thase, M.E. (2003) Challenges in preventing relapse in major depression: Report of a National Institute of Mental Health Workshop on state of the science of relapse prevention in major depression. Journal of Affective Disorders, 77(2), 97-108.
|
[13]
|
Schweitzer, I., Burrows, G. and Tuckwell, V., et al. (2001) Sustained response to open-label venlafaxine in drug-resistant major depression. Journal of Clinical Psycho- pharmacology, 21(2), 185-189.
|
[14]
|
Goldstein, D.J., Lu, Y., Detke, M.J., Wilste, C., Mallinckrodt, C. and Demitrack, M.A. (2004) Duloxetine in the treatment of depression: A double blind placebo controlled comparison with paroxetine. Journal of Clinical Psychopharmacology, 24(4), 389-399.
|
[15]
|
McGrath, P.J., Stewart, J.W., Quitkin, F.M., et al. (2006) Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression. American Journal of Psychiatry, 163 (9), 1542-1548.
|
[16]
|
Perahia, D.G., Gilaberte, I., Wang, F., et al. (2006) Duloxetine in the prevention of relapse of major depressive disorder: a double blind placebo controlled study. British Journal of Psychiatry, 188, 346-353.
|
[17]
|
Geddes, J.R., Carney, S.M., Davis, C., et al. (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: A systemic review. Lancet, 361 (9358), 653-661.
|
[18]
|
Sharma, A., Goldberg, M.J. and Cerimele, B.J. (2000) Pharmacokinetics and safety of duloxetine, a dual serotonin and norepinephrine reuptake inhibitor. Journal Clinical Pharmacology, 40(2), 161-167.
|
[19]
|
Zajecka, J., Amsterdam, J.D., Quitkin, F.M., et al. (1999) Changes in adverse events reported by patients in six months of fluoxetine therapy. Journal of Clinical Psychiatry, 60(6), 389-394.
|
[20]
|
Harman, J.B., Brotman, A.W., Pollock, M.H., Falk, W.E., Biederman, J. and Rosenbaum, J.F. (1990) Flouxetine induced sexual dysfunction. Journal of Clinical Psychiatry, 51(1), 25-27.
|
[21]
|
Detke, M.J., Lu, Y., Goldstein, D.J., Hayes, J.R. and Demitrack, M.A. (2002) Duloxetine, 60 mg once daily for major depressive disorder: A randomized double blind placebo controlled trial. Journal of Clinical Psychiatry, 63(4), 308-315.
|